SCHEMBL5054098

SCHEMBL5054098

CCCCOC(=O)c1ccc2c(c1)N=C(c1cc(Cl)cc(Cl)c1)c1c(cccc1C(N)=O)S2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 7/20 0.45
CNR2 P34972 2/20 0.45
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PDE4D Q08499 1/20 0.36
TP53 P04637 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ESR1 P03372 3/20 0.36
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PLEC Q15149 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5064791 0.92 CNR1 (0.56) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5064695 0.91 CNR1 (0.53) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5064769 0.89 CNR1 (0.49) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5057364 0.89 CNR1 (0.51) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5064591 0.85 CNR1 (0.51) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5057771 0.83 CNR1 (0.46) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5062662 0.80 CNR1 (0.47) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5057305 0.80 ESR1 (0.42) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5063096 0.80 CNR1 (0.44) CNR1CNR2TSHRLMNACYP1A2
SCHEMBL5057597 0.79 CNR1 (0.41) CNR1CNR2TSHRLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH CNR1 1/4885CNR2 2/4885TSHR 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.